Shop Now Contact

TNFR-2/Fc Fusion Protein (Etanercept Biosimilar)

Cat # Size Price Quantity
5027011 mg$400
5027025 mg$800
50270320 mg$2200

  Bulk/Custom

Product Details

CloneEtanercept
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionEtanercept Biosimilar
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsTNF receptor 2, TNFR2
RRIDAB_3739303
Target NameTNFR2, CD120b, TNFRSF1B, p75, p75TNFR, TNFR80, TBPII
Antibody TypeRecombinant
Research AreasT cells, Macrophages, Monocytes, B cells, Co-stimulation, Autoimmunity, Inflammation
See All FormatsClone Etanercept

Background Information

Etanercept is a recombinant fusion protein designed to modulate signaling mediated by tumor necrosis factor (TNF). Structurally, it consists of the extracellular ligand-binding domain of the human TNF receptor 2 (TNFR2, also known as p75) fused to the Fc (fragment crystallizable) portion of human immunoglobulin G1 (IgG1). This fusion creates a soluble dimeric receptor with a molecular weight of approximately 150 kilodaltons (kDa). The molecule effectively mimics the natural TNF receptor but is engineered for enhanced stability, dimerization, and extended circulation in the bloodstream. Etanercept is produced in mammalian expression systems, typically Chinese Hamster Ovary (CHO) cells, to ensure proper folding, assembly, and glycosylation consistent with human proteins.

The TNFR2 extracellular domain within Etanercept retains its biological ability to bind both TNF-α and TNF-β (also called lymphotoxin-α), which are trimeric cytokines belonging to the TNF superfamily. Each Etanercept dimer presents two receptor-binding sites, enabling high-affinity sequestration of soluble and membrane-bound TNF molecules. By binding to TNF, the fusion protein prevents TNF from associating with its native cell surface receptors (TNFR1 and TNFR2), thereby inhibiting receptor-mediated signal transduction. This blockage directly affects downstream intracellular pathways such as the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) cascades, both of which regulate gene expression involved in inflammation, apoptosis, and immune regulation.

The Fc region of human IgG1 in Etanercept contributes to its molecular stability and half-life through interaction with the neonatal Fc receptor (FcRn), which protects it from lysosomal degradation and extends its systemic persistence. Unlike full monoclonal antibodies, Etanercept’s Fc component does not primarily mediate immune effector functions such as antibody-dependent cytotoxicity or complement activation. Overall, Etanercept exemplifies rational fusion-protein design that combines receptor-based ligand trapping with antibody-derived structural resilience, providing a robust model for studying TNF signaling inhibition and receptor–ligand dynamics in immunological research.

Data Sheets

TNFR-2/Fc Fusion Protein (Etanercept Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human TNFα (Adalimumab Biosimilar), Clone Adalimumab

Anti-Human TNF alpha (Infliximab Biosimilar), Clone Infliximab

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.